|
🦁
|
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Stefanie N. Linch,
M. Mcnamara,
William L. Redmond
|
7 |
2015 |
7
🦁
|
|
🐬
|
Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
William L. Redmond,
Stefanie N. Linch,
Melissa J. Kasiewicz
|
7 |
2013 |
7
🐬
|
|
🦁
|
Mouse Eosinophils Possess Potent Antibacterial Properties In Vivo
Stefanie N. Linch,
Ann M. Kelly,
Erin T. Danielson,
R. Pero,
James J. Lee,
J. Gold
|
6 |
2009 |
6
🦁
|
|
🦁
|
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice
Stefanie N. Linch,
Melissa J. Kasiewicz,
M. Mcnamara,
Ian F Hilgart-Martiszus,
M. Farhad,
William L. Redmond
|
6 |
2016 |
6
🦁
|
|
🦁
|
Interleukin 5 is protective during sepsis in an eosinophil-independent manner.
Stefanie N. Linch,
Erin T. Danielson,
Ann M. Kelly,
Raina A Tamakawa,
James J. Lee,
J. Gold
|
6 |
2012 |
6
🦁
|
|
🐢
|
Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis
S. Cohan,
Elisabeth B. Lucassen,
Meghan C Romba,
Stefanie N. Linch
|
5 |
2019 |
5
🐢
|
|
🐜
|
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity
9 auth.
Elizabeth R Sturgill,
Annah S Rolig,
Stefanie N. Linch,
C. Mick,
Melissa J. Kasiewicz,
Zhaoyu Sun,
...
P. Traber,
H. Shlevin,
William L. Redmond
|
4 |
2021 |
4
🐜
|
|
🐬
|
Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade
M. Mcnamara,
Ian F Hilgart-Martiszus,
Diego M Barragan Echenique,
Stefanie N. Linch,
Melissa J. Kasiewicz,
William L. Redmond
|
4 |
2016 |
4
🐬
|
|
🦁
|
Combined OX40 ligation plus CTLA-4 blockade
Stefanie N. Linch,
William L. Redmond
|
4 |
2014 |
4
🦁
|
